JAK2 and B-cell chronic lymphocytic leukemia: From a therapeutic standpoint, targeting JAK2/STAT3, a pathway implicated in certain pathological BMAT expansions (e.g., leukemia-associated), has shown promise: in a chronic lymphocytic leukemia model, inhibiting JAK2/STAT3 reduced pathological marrow adipogenesis more effectively than dietary changes, highlighting a potential intervention to rebalance the niche (Severin et al., 2019).